Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a double-blind placebo-controlled monthly oral MK-8591 for HIV prevention
MOH_2019-09-08_007276Phase 2Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of islatravir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Merck & Co. Primary endpoint: Safety, tolerability, and pharmacokinetics of MK-8591. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
islatravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on MOH_2019-09-08_007276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-08_007276.